Overview

• The NHS has begun a phased rollout of Mounjaro with GPs now prescribing the drug to patients at highest risk of obesity-related complications
• The MHRA cautions that Mounjaro may reduce contraceptive effectiveness and warns women of childbearing age to use two methods of birth control
• Regulators are investigating over 100 suspected deaths linked to GLP-1 weight-loss injections including Mounjaro in the UK
• Patients report common side effects such as severe nausea, diarrhoea, stomach cramps and swelling of the feet and ankles
• While hailed for dramatic weight loss by some users, the long-term safety profile of off-label Mounjaro use remains under close scrutiny